Low-dose spironolactone and chlorthalidone for high blood pressure in chronic kidney disease
Tests low-dose spironolactone and chlorthalidone for high blood pressure in adults with kidney disease.
Plain-language title generated from the registry record
Registry title: LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
Key facts
- Where
- Indianapolis, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07645300, who can take part
Where in United States
- Richard L. Roudebush VA Medical Center, Indianapolis, INIndianapolis, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- VA Office of Research and Development
- Trial code
- NCT07645300
- Record updated
- 12 June 2026
- Original description
The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.Read full original descriptionShow less
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD (LODESTAR) Trial
The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.
Inclusion: Study is limited to US Veterans; GFR estimated by race-independent CKD-EPI formula < 45 ml/min/1.73m2 but 15 mL/min/1.73m2; Hypertension; The investigators will use clinic AOBP of at least 135/85 to define hypertension; Treatment with antihypertensive drugs; This would require the use of at least one antihypertensive drug; One of the drugs should be either an ACE inhibitor or ARB or a beta-blocker at the time of randomization; Serum K 3.5 to 5.2 mEq/L at the time of randomization.
Exclusion: Use of:; SPL; eplerenone; amiloride; triamterene; finerenone; thiazide; thiazide-like drugs (CTD, HCTZ, metolazone, indapamide) or the use of K binders or fludrocortisone in the previous 4 weeks; K supplementation would be allowed; Myocardial infarction, heart failure hospitalization, or stroke 8 weeks prior to randomization; If the patient is only on an alpha blocker, as the sole antihypertensive drug, they will be excluded; Known hypersensitivity or a prior documented adverse reaction to CTD or SPL; Clinic AOBP of >=160/100 mmHg; Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception.